<?xml version='1.0' encoding='utf-8'?>
<document id="25014625"><sentence text="Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential." /><sentence text="With the advent of the direct-acting antiviral agents, significant drug-drug interaction (DDI) potential now exists for patients treated for chronic hepatitis C virus (HCV) infection" /><sentence text=" However, little is known about how often patients with HCV infection use medications that may interact with newer HCV treatments, especially those with cytochrome P450 3A (CYP3A) DDI potential" /><sentence text="" /><sentence text="Using a large US commercial insurance database, medication use and comorbidity burden were examined among adult patients with a chronic HCV diagnosis from 2006 to 2010" /><sentence text=" Medications were examined in terms of total number of prescription claims, proportion of patients exposed, and DDI potential with the prototypical CYP3A direct-acting antiviral agents boceprevir and telaprevir, for which data were available"><entity charOffset="185-195" id="DDI-PubMed.25014625.s6.e0" text="boceprevir" /><entity charOffset="200-210" id="DDI-PubMed.25014625.s6.e1" text="telaprevir" /><pair ddi="false" e1="DDI-PubMed.25014625.s6.e0" e2="DDI-PubMed.25014625.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25014625.s6.e0" e2="DDI-PubMed.25014625.s6.e1" /></sentence><sentence text="" /><sentence text="Patient comorbidity burden was high and increased over the study period" /><sentence text=" Medication use was investigated in 53â€‰461 patients with chronic HCV" /><sentence text=" Twenty-one (53%) of the top 40 most utilized medications were classified as having interaction potential, with 62% of patients receiving at least one of the top 22 interacting medications by exposure" /><sentence text=" Of these, 59 and 41% were listed in a common DDI resource but not in medication-prescribing information, 77 and 77% had not been investigated in DDI studies, 41 and 36% did not have clear recommendations for DDI management, and only 14 and 23% carried a recommendation to avoid coadministration for boceprevir and telaprevir, respectively"><entity charOffset="300-310" id="DDI-PubMed.25014625.s11.e0" text="boceprevir" /><entity charOffset="315-325" id="DDI-PubMed.25014625.s11.e1" text="telaprevir" /><pair ddi="false" e1="DDI-PubMed.25014625.s11.e0" e2="DDI-PubMed.25014625.s11.e0" /><pair ddi="false" e1="DDI-PubMed.25014625.s11.e0" e2="DDI-PubMed.25014625.s11.e1" /></sentence><sentence text="" /><sentence text="Practitioners may expect a medication with CYP3A DDI potential in two-thirds of patients with HCV and may expect almost one-half of the most frequently used medications to have CYP3A DDI potential" /><sentence text=" However, DDI potential may not be reflected in prescribing information" /><sentence text="" /></document>